New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 8, 2014
09:15 EDTANR, IPCI, MIC, WLT, CGI, TXMD, NURO, TFM, GRPN, ABBV, SHPGOn The Fly: Pre-market Movers
HIGHER: Shire (SHPG), up 1% after AbbVie (ABBV) raises buyout offer for fourth time, to GBP 22.44 in cash and 0.8568 AbbVie shares per Shire share. AbbVie shares down about 1% in pre-market trading following the news... Groupon (GRPN), up 5.7% after upgraded at B. Riley... TherapeuticsMD (TXMD), up 21.8% after FBR Capital initiated the stock with an Outperform rating and $34 price target... NeuroMetrix (NURO), up 45% after wearable technology for treatment of chronic pain cleared by FDA... Celadon Group (CGI), up 7% after upgraded at Stifel... Macquarie Infrastructure (MIC), up 6.3% after acquiring remainder of IMTT for $1.025B in cash, stock. LOWER: Intellipharmaceutics (IPCI), down 10% after Q2 earnings lower than expected... The Fresh Market (TFM), down 6.6% after downgraded at Goldman... Walter Energy (WLT), down 4%, Alpha Natural (ANR), down 1%, after coal sector estimates lowered at Morgan Stanley.
News For SHPG;ABBV;GRPN;TFM;NURO;TXMD;CGI;WLT;MIC;IPCI;ANR From The Last 14 Days
Check below for free stories on SHPG;ABBV;GRPN;TFM;NURO;TXMD;CGI;WLT;MIC;IPCI;ANR the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
September 18, 2014
05:50 EDTWLTStocks with implied volatility movement; WLT GPRO
Stocks with implied volatility movement; Walter Energy (WLT) 86, GoPro (GPRO) 95 according to iVolatility.
September 17, 2014
16:00 EDTWLTOptions Update; September 17, 2014
iPath S&P 500 VIX Short-Term Futures down 24c to 27.63. Option volume leaders: AAPL TSLA BAC TWTR AMZN X WLT KO PBR according to Track Data.
07:43 EDTSHPGBofA/Merrill to hold a conference
Subscribe for More Information
September 16, 2014
11:51 EDTSHPGOECD looks to close tax loopholes with new proposals
Subscribe for More Information
September 15, 2014
14:04 EDTWLT, ANRChina coal rules won't materially suppress demand, says Brean Capital
Subscribe for More Information
13:58 EDTWLT, ANRChina to ban imports of dirtier coal, Reuters reports
Subscribe for More Information
10:55 EDTSHPG, ABBVRegulators to determine AbbVie, Shire deal by next month, Reuters says
Subscribe for More Information
08:11 EDTANRAlpha Natural reconfirms coal shipment guidance
Subscribe for More Information
08:01 EDTSHPGShire announces FDA acceptance for filing of sNDA for Vyvanse
Subscribe for More Information
September 12, 2014
07:32 EDTABBVBiogen, AbbVie announce ZINBRYTA DECIDE Phase 3 study results
Biogen (BIIB) and AbbVie (ABBV) announced the full results from the Phase 3 DECIDE clinical trial, which show ZINBRYTA, dosed subcutaneously once a month, demonstrated a statistically significant improvement in reducing disease activity in people with relapsing-remitting multiple sclerosis compared to AVONEX. These results are being presented at the Sixth Triennial Joint Meeting of the Americas Committee for Treatment and Research in Multiple Sclerosis and the European Committee for Treatment and Research in Multiple Sclerosis. Patients on ZINBRYTA demonstrated a statistically significant 45% reduction in annualized relapse rate compared to patients treated with AVONEX. Based on the efficacy and safety data from the ZINBRYTA clinical development program, Biogen Idec and AbbVie plan to file marketing applications for ZINBRYTA with regulatory authorities during 1H15.
September 11, 2014
16:00 EDTWLTOptions Update; September 11, 2014
Subscribe for More Information
05:34 EDTABBVAbbVie reports Humira Phase 3 trial meets primary endpoint
Subscribe for More Information
September 10, 2014
11:44 EDTWLTStocks with call strike movement; WLT MBLY
Walter Energy (WLT) January 5 call option implied volatility increased 4% to 71, Mobileye (MBLY) December 65 call option implied volatility decreased 6% to 64 according to IVolatility.
10:24 EDTABBVEnanta announces AbbVie initiated Phase 2b trial with ABT-493
Enanta (ENTA) announced that AbbVie (ABBV) initiated a phase 2b clinical study with ABT-493, Enanta’s next-generation protease inhibitor. ABT-493 is the second clinical-stage protease inhibitor candidate developed within the Enanta-AbbVie collaboration. The phase 2b study being conducted by AbbVie will evaluate the safety and efficacy of ABT-493 co-administered with ABT-530 in HCV patients. AbbVie has informed Enanta that results from this trial are expected in 2015 and AbbVie plans to start phase 3 development of the combination next year.
08:37 EDTSHPGMedgenics appoints Scott Applebaum as Chief Legal Officer
Subscribe for More Information
07:06 EDTSHPGSangamo plans to submit IND application for hemophilia B in 2Q15
Sangamo BioSciences (SGMO) plans to submit an Investigational New Drug application for the treatment of hemophilia B in Q2 2015. This program, partnered with Shire (SHPG), is the first therapeutic application of Sangamo's zinc finger nuclease-mediated In Vivo Protein Replacement Platform. Sangamo is developing the IVPRP as a generally applicable strategy to provide a one-time, permanent genetic cure for monogenic diseases that are currently managed by protein replacement therapy, which involves costly repeat infusions over the lifetime of the patient.
September 9, 2014
15:11 EDTGRPNGroupon confirms integration with Apple Pay
Groupon (GRPN) announced its integration with Apple Pay, Apple's (AAPL) new mobile payment system for iPhone 6 and iPhone 6 Plus. Groupon said it is one of the first mobile commerce companies to announce integration with Apple Pay, and the new payment option will be available to customers beginning in October.
13:58 EDTGRPNStarbucks, Groupon, OpenTable apps among those to integrate Apple Pay
Subscribe for More Information
September 8, 2014
12:40 EDTABBVFTC sues AbbVie over blocking of AndroGel generics
The Federal Trade Commission has filed a complaint in federal district court charging several pharmaceutical companies with "illegally blocking American consumers’ access to lower-cost versions of the blockbuster drug AndroGel." The FTC's complaint alleges that AbbVie (ABBV) and its partner Besins Healthcare filed baseless patent infringement lawsuits against potential generic competitors to delay the introduction of lower-priced versions of the testosterone replacement drug AndroGel. While the lawsuits were pending, AbbVie then entered into an anticompetitive pay-for-delay settlement agreement with Teva Pharmaceuticals (TEVA) to further delay generic drug competition, the FTC claims. Reference Link
07:15 EDTABBVIBC Life Sciences to hold a conference
10th Annual Cell Line Development & Engineering Conference to be held in Berkeley, California on September 8-10.
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use